Paclitaxel

Durvalumab and PET-directed chemoradiation in advanced esophageal cancer 1:50
Durvalumab and PET-directed chemoradiation in advanced esophageal cancer
Geoffrey Ku • 17 Apr 2023
Combination therapies with vemurafenib in BRAF v600E–mutant cancers 2:04
Combination therapies with vemurafenib in BRAF v600E–mutant cancers
Blessie Elizabeth Nelson • 17 Apr 2023
KEYMAKER-U06 substudy 06A: favezelimab or MK-4380 in esophageal cancer 1:07
KEYMAKER-U06 substudy 06A: favezelimab or MK-4380 in esophageal cancer
Ken Kato • 19 Jan 2023
N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer 2:13
N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer
Saranya Chumsri • 8 Dec 2022
5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC 2:52
5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC
Paolo Tarantino • 8 Dec 2022
EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer 2:54
EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer
Avinash Khadela • 29 Nov 2022
Long-term survival of the Phase II GeparOLA study 1:28
Long-term survival of the Phase II GeparOLA study
Sibylle Loibl • 6 Dec 2022
APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancer 1:56
APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancer
Sara M. Tolaney • 6 Dec 2022
KEYNOTE-061: association between gene expression signatures & outcomes 1:35
KEYNOTE-061: association between gene expression signatures & outcomes
Kohei Shitara • 12 Sep 2022
SYNERGY: 1L chemo-immunotherapy with or without the anti-CD73 antibody oleclumab in advanced TNBC 1:02
SYNERGY: 1L chemo-immunotherapy with or without the anti-CD73 antibody oleclumab in advanced TNBC
Laurence Buisseret • 10 Sep 2022
Combining 1L chemo-immunotherapy with oleclumab in patients with advanced TNBC 1:07
Combining 1L chemo-immunotherapy with oleclumab in patients with advanced TNBC
Laurence Buisseret • 10 Sep 2022
ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC 1:58
ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC
Sara Tolaney • 13 Sep 2022
Unanswered questions in the METEORA-II trial 0:48
Unanswered questions in the METEORA-II trial
Elisabetta Munzone • 11 Sep 2022
KEYNOTE-B10: pembro + carbo + pacli as 1L therapy in recurrent/metastatic HNSCC 1:38
KEYNOTE-B10: pembro + carbo + pacli as 1L therapy in recurrent/metastatic HNSCC
Marcin Dzienis • 12 Sep 2022
METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer 1:06
METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer
Elisabetta Munzone • 11 Sep 2022
Treating metastatic breast cancer with metronomic VEX in the METEORA-II trial 0:53
Treating metastatic breast cancer with metronomic VEX in the METEORA-II trial
Elisabetta Munzone • 11 Sep 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals